GLAXO2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member GLAXO2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2021-04-01 2022-03-31 2021-12-28 INR Lakhs Third quarter Single segment Pharmaceuticals 2021-10-01 2021-12-31 Unaudited Standalone 8079800000.00 105000000.00 8184800000.00 1069800000.00 2137900000.00 -104700000.00 1423900000.00 5800000.00 178700000.00 1586300000.00 6297700000.00 1887100000.00 -179200000.00 1707900000.00 389400000.00 -57100000.00 332300000.00 0.00 1375600000.00 169300000.00 48600000.00 120700000.00 0.00 1496300000.00 0.00 1496300000.00 0.00 0.00 1694100000.00 10 8.12 8.12 0.71 0.71 8.83 8.83 0.00 0.00 0.00 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 7th February, 2022. 2. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter and nine months ended 31st December, 2021. 3. Other income for the quarter ended 31st December 2021 includes interest on income tax refund of Rs.Nil (quarter ended 31st December 2020 of Rs. 634 Lakhs). 4. Exceptional items for the quarter ended 31st December, 2021 of Rs.1792 Lakhs comprise of: a. Additional charge of Rs. 2008 lakhs on account of restructuring of the commercial functions to deliver a sustainable and efficient sales force deployment model. b. Credit of Rs. 170 lakhs following the disposal of the Asset held for sale at Vemgal and consequent post-transaction closing adjustments. c. Compensation received from the government authorities on surrender of parcel of land Rs. 190 lakhs. d. Others Rs. 144 lakhs Exceptional items for the quarter ended 31st December, 2020 of Rs.1053 Lakhs comprise of reversal of provisions on account of product recall of Zinetac Rs.893 Lakhs, profit on sale of property Rs.184 Lakhs and other charges Rs.24 Lakhs. 5. The Board of Directors ('Board') of the Company at their meeting held on 26th July 2021 had approved the transfer of the trademarks ‘pertaining to ‘Iodex’ and ‘Ostocalcium’ brands (“ Brands”) in India along with legal, economic, commercial and marketing rights of such brands and other identified assets to GlaxoSmithKline Asia Private Limited with respective values aggregating to Rs. 164901 lakhs. Subsequently, the transfer was approved by the shareholders of the company on 15th September 2021 and the company has now received the necessary approvals from the regulator on 21st January 2022. Consequently, the same has been disclosed as Discontinuing Operations in accordance with Ind AS 105.The transaction is expected to be consummated by the next quarter. 6. The spread of Covid-19 is having an unprecedented impact on people and economy. The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade receivables, tangible assets, intangible assets and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial results has used internal and external sources of information. The impact assessment of Covid-19 is a continuing process given the uncertainties and the Company will continue to closely monitor the developments. 7. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. 8. Previous periods' figures have been re-grouped / re-classified wherever necessary. Single segment 2021-04-01 2021-12-31 Unaudited Standalone 24255900000.00 572800000.00 24828700000.00 4193200000.00 5453400000.00 -45200000.00 4701900000.00 17200000.00 528400000.00 4128500000.00 18977400000.00 5851300000.00 -179200000.00 5672100000.00 1477300000.00 -129700000.00 1347600000.00 0.00 4324500000.00 559300000.00 156900000.00 402400000.00 0.00 4726900000.00 0.00 4726900000.00 0.00 0.00 1694100000.00 10 25.53 25.53 2.38 2.38 27.91 27.91 0.00 0.00 0.00 Other Expenses 1586300000.00 Other Expenses 4128500000.00